MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Exclusion Criteria

• •POEMS syndrome
• •Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
• •History of active autoimmune disorders
• •Any form of primary immunodeficiency
• •History of severe immune-mediated adverse event with prior immunomodulatory treatment
• •Stem cell transplant within 12 weeks prior to enrollment
• •Active graft versus host disease other than Grade 1 skin involvement, or that requiring immunosuppressive treatment
• •Requirement for systemic immune suppressive medication
• •Active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, known HIV or AIDS related illness and SARS-CoV2
• •Previous administration with an investigational drug within 4 weeks or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
• •Known or suspected hypersensitivity to component of elranatamab (PF-06863135), murine and bovine products
• •Live attenuated vaccine within 4 weeks